The key drivers of increased investor interest in AstraZeneca are the strong performance of its oncology and cardiovascular ...

Jan 13 (Reuters) - Global drugmakers are ramping up U.S. manufacturing and stockpiling inventory as the Trump administration considers imposing a 100% tariff on imported branded and patented medicines ...

A phase 3 study of AstraZeneca’s ceralasertib has missed its primary endpoint, dealing another blow to efforts to use a synthetic lethal mechanism to overcome resistance to immuno-oncology drugs. The ...

AstraZeneca said its experimental drug ceralasertib in combination with approved cancer treatment Imfinzi didn’t meet the primary goal of a late-stage clinical trial for advanced lung cancer. The U.K.

AstraZeneca will end U.S. commercial sales of Andexxa Dec. 22, citing safety concerns raised in postmarketing data and a recent trial, according to a Dec. 18 FDA news release. Andexxa, a recombinant ...

Pfizer Inc. provided early 2025 and 2026 guidance, projecting flat-to-declining revenues and EPS, highlighting persistent growth and profitability challenges. Pfizer faces major patent expiries, ...

Pfizer Inc. (NYSE: PFE) on Tuesday gave a first glimpse of its fiscal 2026 guidance. The U.S. pharma giant sees 2026 adjusted earnings of $2.80-$3.00 per share compared to the consensus of $3.06.

Seven years after the FDA's accelerated approval of bleeding reversal agent Andexxa, which was then under the ownership of Portola Pharmaceuticals, the drug's round trip on the U.S. market is coming ...

Pfizer stock has been a weak performer, declining by about 7% through 2025. Things could remain mixed over 2026 as well, with the company guiding for revenues of $59.5-$62.5 billion and adjusted EPS ...

With the drug still at an early stage of development, Pfizer has negotiated an opt-out clause in case trials do not go to plan Fosun Pharma's revenues from innovative drugs jumped 18.09% in the first ...